Logo

OABI

OmniAb, Inc.

OABI

OmniAb, Inc. • NASDAQ
$1.81 ▼ -2.69% (-0.05)
Market Cap $194.80 M
52w High $4.17
52w Low $1.22
Dividend Yield 0%
P/E -3.07
Volume 234.65K
Outstanding Shares 107.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.239M ▼ $15.719M ▼ $-16.525M ▼ -738.053% ▼ $-0.14 ▲ $-10.709M ▲
Q2-2025 $3.897M ▼ $19.854M ▼ $-15.875M ▲ -407.365% ▲ $-0.15 ▲ $-14.57M ▼
Q1-2025 $4.154M ▼ $22.998M ▼ $-18.2M ▼ -438.132% ▼ $-0.17 ▼ $-14.101M ▼
Q4-2024 $10.804M ▲ $26.684M ▲ $-13.068M ▲ -120.955% ▲ $-0.12 ▲ $-8.274M ▲
Q3-2024 $4.172M $23.936M $-16.373M -392.45% $-0.16 $-14.837M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $59.5M ▲ $309.69M ▲ $32.246M ▼ $277.444M ▲
Q2-2025 $41.615M ▼ $295.674M ▼ $33.61M ▲ $262.064M ▼
Q1-2025 $43.595M ▼ $306.182M ▼ $32.666M ▼ $273.516M ▼
Q4-2024 $59.434M ▲ $325.558M ▼ $37.94M ▼ $287.618M ▼
Q3-2024 $59.381M $331.554M $39.826M $291.728M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-16.525M ▼ $-9.763M ▼ $-7.665M ▼ $27.684M ▲ $10.256M ▲ $-9.945M ▼
Q2-2025 $-15.875M ▲ $-5.146M ▲ $12.299M ▲ $236K ▲ $7.389M ▲ $-5.311M ▲
Q1-2025 $-18.2M ▼ $-15.872M ▼ $-878K ▼ $44K ▼ $-16.706M ▼ $-16.081M ▼
Q4-2024 $-13.068M ▲ $-3.872M ▲ $385K ▼ $3.849M ▼ $362K ▼ $-3.918M ▲
Q3-2024 $-16.373M $-6.578M $4.449M $8.571M $6.442M $-6.73M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $10.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement OmniAb’s income statement looks like that of a platform biotech still in the build‑out phase. Revenue is very small and has stayed roughly flat over the past several years, while operating costs are much higher than sales. The company has reported operating and net losses every year, and those losses have generally grown as it invests in its platform and partnerships. This means the business is not yet self‑funding and depends on external capital or partner payments to support ongoing operations.

Balance Sheet

Balance Sheet The balance sheet shows a business with a solid equity base and only modest use of debt so far. Assets have built up over time but have recently edged down, which can reflect cash use and limited new capital coming in. Cash levels are positive but not large relative to the company’s loss profile, suggesting a need for careful cash management. Overall, financial leverage is low, but the balance sheet does not appear strong enough on its own to support many years of continued losses without additional funding or improved cash inflows.

Cash Flow

Cash Flow Cash flow patterns are consistent with an early‑stage platform company. Operating cash flow has hovered around break‑even to modestly negative, turning more clearly negative in the most recent period as spending outweighs cash receipts. Capital spending is very light, so free cash flow is driven mostly by operating performance rather than large investments in equipment or facilities. The business currently consumes cash rather than generates it, though the burn rate appears controlled rather than extreme.

Competitive Edge

Competitive Edge OmniAb occupies a specialized niche in antibody discovery with a broad suite of transgenic animal platforms and AI‑enabled tools. Its multi‑species approach and focus on difficult targets like ion channels help differentiate it from more generic antibody discovery competitors. A large and growing roster of partners, multiple active programs, and a few approved products built on its technology all point to meaningful external validation. At the same time, the company depends heavily on partners’ success in clinical trials and commercialization, so its revenue potential is tied to forces it does not fully control and to a highly competitive biopharma landscape.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of OmniAb’s strategy and identity. The company has repeatedly expanded its platform with new animal models, single‑domain antibody technologies, and AI‑driven discovery and screening tools. Recent launches like the xPloration high‑throughput screening system and the OmniDeep AI suite show a push to stay on the cutting edge and deepen integration of software with biology. This sustained R&D effort is costly in the short term but is central to maintaining the platform’s appeal, attracting new partners, and broadening the range of drug programs that can originate from OmniAb’s technologies.

Summary

Overall, OmniAb looks like a technologically rich but financially early‑stage platform biotech. The company has carved out a distinctive position in antibody discovery, backed by multiple transgenic species, AI‑enabled tools, and a sizable partner ecosystem that provides strong scientific and commercial validation. Financially, revenue remains small relative to spending, profitability is not yet in sight, and the business continues to burn cash, albeit at a measured pace and with low leverage. The long‑term story hinges on continued innovation, wider adoption of its newer platforms, and, above all, the clinical and commercial success of antibody programs advanced by its partners, which introduces both significant upside potential and meaningful execution and timing risk.

NEWS

November 17, 2025 · 5:23 PM UTC

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

Read more

November 4, 2025 · 4:05 PM UTC

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

Read more

October 16, 2025 · 8:00 AM UTC

OmniAb to Participate in Three Investor Conferences in November

Read more

October 14, 2025 · 8:00 AM UTC

OmniAb to Report Third Quarter 2025 Financial Results on November 4

Read more